Trial Profile
A Two-part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Oral Doses of Pazopanib in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Acute myeloid leukaemia; Age-related macular degeneration; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gallbladder cancer; Glioma; Hereditary haemorrhagic telangiectasia; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Sarcoma; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 16 Sep 2015 New trial record